Active Component of Antrodia cinnamomea Mycelia Targeting Head and Neck Cancer Initiating Cells through Exaggerated Autophagic Cell Death
Figure 2
YMGKI-1 treatment suppresses xenograft tumor growth in vivo. (a) SAS cells pretreated with YMGKI-1 (0, 25, 50 μg/mL) for 24 hr were injected into the subcutaneous space of nude mice. Representative image of nude mice displaying tumor growth caused by either control SAS cells (DMSO) injected into the left subcutaneous space or SAS cells with pretreatment of YMGKI-1 (25 μg/mL) injected into the right subcutaneous space on day 20 (middle left panel). Image of dissected tumors collected on day 30 (left column: DMSO (control), middle column: treated with 25 μg/mL, and right column: treated with 50 μg/mL) (middle right panel). The tumor growth curves on nude mice inoculated with YMGKI-1 pretreated SAS cells were recorded (lower panel). (b) Therapeutic model to demonstrate the effect of YMGKI-1 treatment on inhibiting tumor growth. Parental SAS cells (1 × 106 cells) were subcutaneously implanted into the right back of nude mice and allowed to develop tumors to a size around 0.1 cm3. On days 11, 13, and 17 after cells implantation, nude mice bearing SAS-derived tumors were intraperitoneally injected with YMGKI-1 (20 mg/kg) or DMSO (as control). On day 24, the image of mice, including control mouse (DMSO) on the right side plus experimental mouse (YMGKI-1 treatment) on the left side, was collected (middle panel). Additionally, the tumor growth curves were recorded (bottom panel). Error bars correspond to SD (; *; **).
